Making Aprocitentan Generics? These Five Barriers Decide Everything

Time：2026-09-23

Figure 1 The generic window for aprocitentan is opening, but the real barriers lie beyond it

Aprocitentan (Vanrafia®) was approved in both China and the United States in 2025 for the reduction of proteinuria in adults with IgA nephropathy. The compound patent is no longer the main obstacle — before you commit to a programme, work through these five barriers.

01 Patents: Run an FTO First, Don’t Trust “It’s Expired”

The US Orange Book lists ten patents:

• The earliest formulation patent expires in July 2034

• The “improved renal function” method-of-use patent runs to March 2043 (US12582631)

• The Chinese stable-formulation patent CN105517541 remains in force; confirm the exact expiry date against official CNIPA data

A generic can only enter after expiry or a successful challenge — realistically 2040 or later. Run a dedicated freedom-to-operate search; do not rely on second-hand conclusions.

02 Formulation: 0.75 mg and Antioxidant Excipients

A low-dose presentation whose formulation includes antioxidant excipients such as L-cysteine hydrochloride (per the FDA label excipient list).

03 Impurity Profile: The Biggest Technical Barrier

No pharmacopoeia covers the molecule, so the profile has to be built from scratch. Chiral, process, degradation and genotoxic impurities all require reference standards — miss one and stability studies, method validation and the CTD all stall.

04 Reference Standards: They Set Your Filing Rhythm

Lead times for reference standards routinely hold up programmes. Three things to check in a supplier:

✅ Purity and a complete analytical data package

✅ ISO 17034 quality system accreditation

✅ Capability to custom-synthesise

05 Competition: Track Three Timelines at Once

Sparsentan received full FDA approval in September 2024, and the domestic candidate SC0062 is already in Phase III. Originator upgrades, competitor launches and reimbursement negotiations must all be plotted on the same timeline.

In one sentence: whether you can genericise, and when, depends on a risk map — patent FTO plus impurity profile. Draw the map first, then set the pace of your programme.

We already stock the full aprocitentan impurity range: chiral enantiomers, desmethyl, desbutyl, amide and methyl ester impurities (purity ≥98%, supplied with CoA/MS/NMR/HPLC data). Routine impurities ship in 15 working days; complex molecules in about four weeks.

View the full aprocitentan standard range →

ANAB ISO 17034 QCS holds ANAB ISO 17034 accreditation. Our reference standard production and value assignment processes meet the international requirements for competence of reference material producers, providing data with international mutual recognition for NMPA, EMA and FDA submissions.